A Risk Score Model Based on TGF-β Pathway-related Genes Predicts Survival, Tumor Microenvironment and Immunotherapy for Liver Hepatocellular Carcinoma

Overview

Journal Proteome Sci

Publisher Biomed Central

Date 2022 Jun 22

PMID 35733217

Authors

Jingsheng Liao

Qi Liu

Jingtang Chen

Zhibin Lu

Huiting Mo

Jun Jia

Affiliations

Soon will be listed here.

Abstract

Background: Transforming growth factor-beta (TGF-β) signal is an important pathway involved in all stages of liver hepatocellular carcinoma (LIHC) initiation and progression. Therefore, targeting TGF- β pathway may be a potential therapeutic strategy for LIHC. Prediction of patients' tumor cells response requires effective biomarkers.

Methods: From 54 TGF-β-related genes, this research determined the genes showing the greatest relation to LIHC prognosis, and developed a risk score model with 8 TGF-β-related genes. The model divided LIHC patients from different datasets and platforms into low- and high-risk groups. Multivariate Cox regression analysis confirmed that the model was an independent prognostic factor for LIHC. The differences in genetic mutation, immune cell infiltration, biological pathway, response to immunotherapy or chemotherapy, and tumor microenvironment in LIHC samples showing different risks were analyzed.

Results: Compared with low-risk group, in the training set and test set, high-risk group showed shorter survival, lower stromal score and higher M0 macrophages scores, regulatory T cells (Tregs), helper follicular T cells. Moreover, high-risk samples showed higher sensitivity to cisplatin, imatinib, sorafenib and salubrinal and pyrimethamine. High-risk group demonstrated a significantly higher Tumor Immune Dysfunction and Exclusion (TIDE) score, but would significantly benefit less from taking immunotherapy and was less likely to respond to immune checkpoint inhibitors.

Conclusions: In general, this work provided a risk scoring model based on 8 TGF-β pathway-related genes, which might be a new potential tool for predicting LIHC.

Citing Articles

Establishment of a Lactylation-Related Gene Signature for Hepatocellular Carcinoma Applying Bulk and Single-Cell RNA Sequencing Analysis.

Yu L, Shi Y, Zhi Z, Li S, Yu W, Zhang Y Int J Genomics. 2025; 2025:3547543.

PMID: 39990773 PMC: 11845269. DOI: 10.1155/ijog/3547543.

Transforming growth factor-β (TGF-β) signaling pathway-related genes in predicting the prognosis of colon cancer and guiding immunotherapy.

Chen J, Ji C, Liu S, Wang J, Wang C, Pan J Cancer Pathog Ther. 2024; 2(4):299-313.

PMID: 39371100 PMC: 11447362. DOI: 10.1016/j.cpt.2023.12.002.

TGF-β based risk model to predict the prognosis and immune features in glioblastoma.

Liu H, Wei Z, Zhang Y, Shi K, Li J Front Neurol. 2023; 14:1188383.

PMID: 37456651 PMC: 10343447. DOI: 10.3389/fneur.2023.1188383.

The Role of TGF-β Signaling in Saphenous Vein Graft Failure after Peripheral Arterial Disease Bypass Surgery.

He C, Ye P, Zhang X, Esmaeili E, Li Y, Lu P Int J Mol Sci. 2023; 24(12).

PMID: 37373529 PMC: 10299557. DOI: 10.3390/ijms241210381.

Development of a TGF-β signaling-related genes signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma.

Wu X, Xie W, Gong B, Fu B, Chen W, Zhou L Front Oncol. 2023; 13:1124080.

PMID: 36776317 PMC: 9911835. DOI: 10.3389/fonc.2023.1124080.

References

Kavanagh E, Joseph B . The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochim Biophys Acta. 2011; 1816(1):50-6. DOI: 10.1016/j.bbcan.2011.03.002. View

Mazzoccoli G, Pazienza V, Panza A, Valvano M, Benegiamo G, Vinciguerra M . ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer. J Cancer Res Clin Oncol. 2011; 138(3):501-11. DOI: 10.1007/s00432-011-1126-6. View

Chen J, Zaidi S, Rao S, Chen J, Phan L, Farci P . Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway. Gastroenterology. 2017; 154(1):195-210. PMC: 6192529. DOI: 10.1053/j.gastro.2017.09.007. View

Katz L, Likhter M, Jogunoori W, Belkin M, Ohshiro K, Mishra L . TGF-β signaling in liver and gastrointestinal cancers. Cancer Lett. 2016; 379(2):166-72. PMC: 5107316. DOI: 10.1016/j.canlet.2016.03.033. View

Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E . T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009; 11(2):R15. PMC: 2688939. DOI: 10.1186/bcr2234. View

Khemlina G, Ikeda S, Kurzrock R . The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017; 16(1):149. PMC: 5577674. DOI: 10.1186/s12943-017-0712-x. View

Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov J, Tamayo P . The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2016; 1(6):417-425. PMC: 4707969. DOI: 10.1016/j.cels.2015.12.004. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Lin Z, Xu Q, Miao D, Yu F . An Inflammatory Response-Related Gene Signature Can Impact the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma. Front Oncol. 2021; 11:644416. PMC: 8019928. DOI: 10.3389/fonc.2021.644416. View

10.

Roh W, Chen P, Reuben A, Spencer C, Prieto P, Miller J . Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017; 9(379). PMC: 5819607. DOI: 10.1126/scitranslmed.aah3560. View

11.

Cibulskis K, Lawrence M, Carter S, Sivachenko A, Jaffe D, Sougnez C . Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-9. PMC: 3833702. DOI: 10.1038/nbt.2514. View

12.

Zhu Z, Xu J, Li L, Ye W, Chen B, Zeng J . Comprehensive analysis reveals , , and as the novel prognostic markers in gastric cancer. Transl Cancer Res. 2022; 9(7):4093-4110. PMC: 8798080. DOI: 10.21037/tcr-20-211. View

13.

Sun Z, Lu Z, Li R, Shao W, Zheng Y, Shi X . Construction of a Prognostic Model for Hepatocellular Carcinoma Based on Immunoautophagy-Related Genes and Tumor Microenvironment. Int J Gen Med. 2021; 14:5461-5473. PMC: 8436260. DOI: 10.2147/IJGM.S325884. View

14.

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

15.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

16.

Long J, Wang A, Bai Y, Lin J, Yang X, Wang D . Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine. 2019; 42:363-374. PMC: 6491941. DOI: 10.1016/j.ebiom.2019.03.022. View

17.

Ler S, Leung C, Khin L, Lu G, Salto-Tellez M, Hartman M . HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population. Oncol Rep. 2015; 34(5):2238-50. PMC: 4583520. DOI: 10.3892/or.2015.4263. View

18.

Jin Y, Liang Z, Zhou W, Zhou L . Expression, clinicopathologic and prognostic significance of plasminogen activator inhibitor 1 in hepatocellular carcinoma. Cancer Biomark. 2019; 27(3):285-293. DOI: 10.3233/CBM-190560. View

19.

Blanche P, Dartigues J, Jacqmin-Gadda H . Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013; 32(30):5381-97. DOI: 10.1002/sim.5958. View

20.

Fabregat I, Moreno-Caceres J, Sanchez A, Dooley S, Dewidar B, Giannelli G . TGF-β signalling and liver disease. FEBS J. 2016; 283(12):2219-32. DOI: 10.1111/febs.13665. View